Immune checkpoints, including PD-1/PD-L1 and CTLA-4, have gained attention in cancer-associated therapy via immune surveillance and escape (Dall'Olio et al., 2022; Doroshow et al., 2021). The gene discussed is CTLA4; the disease is cancer.